Fri, May 9, 11:40 AM (7 days ago)
**Summary of uniQure N.V. (QURE) Q1 2025 Financial Performance** **Revenue and Profit Margins:** - **Revenue:** $1.6 million, down from $8.5 million in Q1 2024. - **Operating Expenses:** $47.2 million, down from $63.9 million in Q1 2024. - **Net Loss:** $43.6 million, an improvement from $65.6 million in Q1 2024. - **Cash and Cash Equivalents:** $217.2 million, up from $158.9 million in Q1 2024. **Cash Flow:** - **Net Cash Used in Operating Activities:** $44.1 million, an improvement from $60.6 million in Q1 2024. - **Net Cash Generated from Investing Activities:** $20.1 million, down from $64.0 million in Q1 2024. - **Net Cash Generated from Financing Activities:** $80.6 million, up from nil in Q1 2024. **Earnings Changes:** - **Earnings per Share (EPS):** $(0.82), improved from $(1.36) in Q1 2024. **Quarterly Performance Discussion:** - **Revenue Breakdown:** License revenues were $1.6 million, down from $1.2 million in Q1 2024. Collaboration revenues were nil, down from $3.3 million in Q1 2024. Contract manufacturing revenues were nil, down from $4.0 million in Q1 2024. - **Operating Expenses:** Research and development expenses were $36.1 million, down from $40.7 million in Q1 2024. Selling, general, and administrative expenses were $10.9 million, down from $13.9 million in Q1 2024. - **Other Income:** $8.3 million, up from $1.4 million in Q1 2024, primarily due to a one-time sale of critical reagents to Genezen. **Trends and Uncertainties:** - **Cash Position:** As of March 31, 2025, uniQure had $410.4 million in cash and cash equivalents and investment securities. - **Future Operations Impact:** uniQure expects its current cash position to fund operations through the second half of 2027. However, this estimate is based on assumptions that may prove incorrect, and the company could exhaust its available capital resources sooner than expected. - **Debt and Leases:** uniQure has an outstanding loan of $50.0 million with Hercules, due in January 2027. The company also has fixed lease payment obligations of $22.8 million. - **Commitments:** uniQure has commitments related to the acquisition of uniQure France SAS, with potential milestone payments of $166.2 million associated with Phase III development and approval of AMT-260. **Future Outlook:** - uniQure's future capital requirements will depend on various factors, including the progress of its clinical trials, regulatory interactions, and the need for additional resources. The company may need to raise additional funding through equity offerings, debt financings, or strategic alliances to support its operations and development programs.